All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2020-11-10.
From the record
Novavax, Inc.'s filings since 2017 show 2 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2019-04-12); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2020-11-10) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+61.1% a year over 10 filed years; profitable in 1 of 10.
From the record
Novavax, Inc.'s 10 filed years say what it did: revenue went from $15 million in fiscal 2016 to $1.1 billion in fiscal 2025, up 61.1% a year; it rose in 6 of 9 years; the deepest fall was 66% from fiscal 2022 to fiscal 2024; net income was positive in 1 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 3.8/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Novavax, Inc.'s shareholder treatment is put at 3.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 38% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
Leverage 111%: owes 111¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Novavax, Inc.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 89 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 111 cents per dollar of assets, and net share issuance: its share count grew 13.7% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 30% of 102 in its family; net margin 39.2%.
From the record
Novavax, Inc.'s standing among 102 graded names in its industry family: revenue of $1.1 billion in fiscal 2025 ranks in the top 9% by size; a net margin of 39.2% ranks in the top 4%; revenue growth of -17.2% a year over the last 3 filed years ranks in the bottom 25% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 39% of 110 in its family for leadership; chief executive since 2023.
From the record
Novavax, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Jacobs, John C (President and CEO, as filed), filing under that title since 2023-01-25, 3.8 years (bottom 39% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 3.9 years (bottom 20%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (top 43%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 48% of 92 in its family for room to expand.
From the record
Novavax, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $241 million against no long-term debt tagged leaves 20.5% of its assets as net cash, bottom 40% of its family; cash from operations less capital spending is -21.8% of revenue (top 26%); a gross margin of 93.5% (top 27%); research spending of 30.5% of revenue (bottom 19%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 46% of 100 in its family for growth drivers.
From the record
Novavax, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -17.2% a year over the last three filed years against 61.1% over all 10, slowing (bottom 8% of its family); the newest year grew 64.8% (top 27%); research spending grew -34.8% a year (bottom 5%); capital spending grew 247.2% a year (top 1%) (its annual reports). Novavax, Inc. reported 3 product lines in fiscal 2025: Nuvaxovid Sales at $625 million (56%), Licensing Royalties and Other at $438 million (39%), Supply Sales at $60 million (5%); 2 of 3 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 23% of 72 in its family for expectations against reality.
From the record
Novavax, Inc.'s newest year against its own record: revenue of $1.1 billion in fiscal 2025 came in 180.6% above the $400 million its prior three years' pace pointed to (top 15% of its family); net income of $440 million against a prior three-year average of $464 million (top 9%); a net margin of 39.2% against -38.7% before (top 45%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made